Cargando…

Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients

BACKGROUND AND AIM: Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract with the potential to progress to a severe debilitating state. Treatment with biological agents is highly efficient, improving both short-term outcomes and long-term prognosis. Nonetheless...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagnini, Cristiano, Siakavellas, Spyros I., Bamias, Giorgos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079437/ https://www.ncbi.nlm.nih.gov/pubmed/30116266 http://dx.doi.org/10.1155/2018/6317057

Ejemplares similares

The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
por: Evangelatos, Gerasimos, et al.
Publicado: (2022)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Intestinal-Specific TNFα Overexpression Induces Crohn’s-Like Ileitis in Mice
por: Bamias, Giorgos, et al.
Publicado: (2013)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Atypical Mycobacterial Infection Presenting as Persistent Skin Lesion in a Patient with Ulcerative Colitis
por: Bamias, Giorgos, et al.
Publicado: (2011)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn’s disease naive to anti-TNF agents
por: Eder, Piotr, et al.
Publicado: (2015)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
por: Kostas, Athanasios, et al.
Publicado: (2017)

Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis
por: Kaltsa, Garyfallia, et al.
Publicado: (2016)

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
por: Hanić, Maja, et al.
Publicado: (2023)

TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003)

Can We Predict the Efficacy of Anti-TNF-α Agents?
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2017)

Understanding the biology and use of anti-TNF agents in JIA – interim results
por: Lovell, Daniel J, et al.
Publicado: (2012)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
por: Mantzaris, Gerassimos J., et al.
Publicado: (2015)

Anti-TNF Exposure during Pregnancy in Crohn's Disease Patients
por: Silva, Elen Farinelli de Campos, et al.
Publicado: (2018)

PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE
por: dos SANTOS, Byanca Rossetti Moreira, et al.
Publicado: (2020)

Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
por: Hirai, Fumihito, et al.
Publicado: (2019)

Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease
por: Bamias, Giorgos, et al.
Publicado: (2016)

Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
por: Tynjälä, P, et al.
Publicado: (2008)

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2023)

Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
por: Adegbola, Samuel O., et al.
Publicado: (2017)

Regulatory T cells in Crohn's disease following anti‐TNF‐α therapy
por: Chiba, Toshimi, et al.
Publicado: (2019)

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn’s Disease
por: Boronat-Toscano, Albert, et al.
Publicado: (2022)

Assessment of Dietary Adequacy and Quality in a Sample of Patients with Crohn’s Disease
por: Karachaliou, Alexandra, et al.
Publicado: (2022)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
por: Schwartzman, Sergio, et al.
Publicado: (2004)

Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
por: Miyazaki, Haruka, et al.
Publicado: (2022)

Biological agents targeting beyond TNF-alpha
por: Sharma, Rashmi, et al.
Publicado: (2008)

Transmembrane TNF-α: structure, function and interaction with anti-TNF agents
por: Horiuchi, Takahiko, et al.
Publicado: (2010)

Disseminated Tuberculosis in a Patient Taking Anti-TNF Therapy for Crohn's Disease
por: Wang, Ming-Hsi, et al.
Publicado: (2015)

Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease
por: Lykowska-Szuber, Liliana, et al.
Publicado: (2021)

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2013)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ve1g4ed1d9o7dnvoaei47665oe